Cathepsin S, a new serum biomarker of sarcoidosis discovered by transcriptome analysis of alveolar macrophages.
biomarkers
cathepsins
macrophages
sarcoidosis
transcriptome
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
08
2018
accepted:
20
08
2018
entrez:
2
6
2020
pubmed:
1
1
2019
medline:
15
7
2020
Statut:
ppublish
Résumé
Development of reliable new biomarkers remains crucial to improve diagnosis and assessing disease activity in sarcoidosis. The objective of this study was to seek such markers from the gene expression signature of alveolar macrophages by transcriptome analysis. Pooled RNA extracted from alveolar macrophages from patients with active sarcoidosis and control patients was subjected to transcriptome analysis using microarrays. Expressed gene intensity in sarcoidosis relative to that in control was calculated. We measured serum cathepsin S (CTSS) concentrations in 89 healthy volunteers, 107 patients with sarcoidosis, 26 with interstitial pneumonia, 150 with pneumoconiosis, and 76 with pulmonary mycobacteriosis by the enzyme-linked immunosorbent assay. Among 12 genes with ratios higher than that of a housekeeping gene, we selected CTSS for scrutinizing protein expression in serum because of the feasibility of the protein assay. CTSS concentrations were significantly increased in sarcoidosis compared with not only controls but also all the other lung diseases. Receiver operating characteristics curve for sarcoidosis and parenchymal lung diseases revealed an area under the curve of 0.800 (95% confidence interval, 0.751-0.850; p=1.4 x 10 CTSS has the potential to be a useful biomarker in sarcoidosis.
Sections du résumé
BACKGROUND
BACKGROUND
Development of reliable new biomarkers remains crucial to improve diagnosis and assessing disease activity in sarcoidosis. The objective of this study was to seek such markers from the gene expression signature of alveolar macrophages by transcriptome analysis.
METHODS
METHODS
Pooled RNA extracted from alveolar macrophages from patients with active sarcoidosis and control patients was subjected to transcriptome analysis using microarrays. Expressed gene intensity in sarcoidosis relative to that in control was calculated. We measured serum cathepsin S (CTSS) concentrations in 89 healthy volunteers, 107 patients with sarcoidosis, 26 with interstitial pneumonia, 150 with pneumoconiosis, and 76 with pulmonary mycobacteriosis by the enzyme-linked immunosorbent assay.
RESULTS
RESULTS
Among 12 genes with ratios higher than that of a housekeeping gene, we selected CTSS for scrutinizing protein expression in serum because of the feasibility of the protein assay. CTSS concentrations were significantly increased in sarcoidosis compared with not only controls but also all the other lung diseases. Receiver operating characteristics curve for sarcoidosis and parenchymal lung diseases revealed an area under the curve of 0.800 (95% confidence interval, 0.751-0.850; p=1.4 x 10
CONCLUSIONS
CONCLUSIONS
CTSS has the potential to be a useful biomarker in sarcoidosis.
Identifiants
pubmed: 32476947
doi: 10.36141/svdld.v36i2.7620
pii: SVDLD-36-141
pmc: PMC7247107
doi:
Substances chimiques
Biomarkers
0
Cathepsins
EC 3.4.-
cathepsin S
EC 3.4.22.27
Types de publication
Journal Article
Langues
eng
Pagination
141-147Informations de copyright
Copyright: © 2019.
Références
World J Gastroenterol. 2014 Mar 14;20(10):2564-77
pubmed: 24627592
Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):829-33
pubmed: 1672587
Inflammation. 2009 Oct;32(5):310-4
pubmed: 19582562
EMBO J. 2008 Jan 9;27(1):1-5
pubmed: 18046453
Chest. 2010 Jun;137(6):1391-7
pubmed: 20081103
Chest. 2003 Jul;124(1):186-95
pubmed: 12853522
Eur Respir J. 2014 Oct;44(4):985-93
pubmed: 25142485
Thorax. 1996 Aug;51(8):777-80
pubmed: 8795663
Mediators Inflamm. 2005 Aug 14;2005(3):121-30
pubmed: 16106097
Sarcoidosis. 1994 Sep;11(2):102-9
pubmed: 7809492
PLoS One. 2013 Aug 05;8(8):e70630
pubmed: 23940611
Respir Res. 2013 Feb 11;14:18
pubmed: 23399022
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Eur Respir J. 2013 Jun;41(6):1331-9
pubmed: 23060632
Respir Med. 2007 Aug;101(8):1687-95
pubmed: 17446058
Am J Med. 1975 Sep;59(3):365-72
pubmed: 169692
Intern Med. 2010;49(9):847-51
pubmed: 20453406
Int Immunopharmacol. 2015 Mar;25(1):174-9
pubmed: 25623898
Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73
pubmed: 10560120
Immunol Rev. 1999 Dec;172:121-9
pubmed: 10631942
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Nat Rev Immunol. 2003 Jun;3(6):472-82
pubmed: 12776207
Br J Haematol. 2012 Jun;157(6):709-17
pubmed: 22489537